Table 2 Safety of selected regimens... | American Society of Hematology

Table 2

Safety of selected regimens

Regimen	Grade 3-4 hematologic toxicities			Grade 3-4 nonhematologic toxicities
Regimen	Neutropenia, %	Thrombocytopenia, %	Anemia, %	Thromboembolism, %	Neuropathy, %	Infection, %	Second primary cancer, %
Stem cell transplantation
BD¹⁷	5	2.9	4.2	1.7	7.1	8.8
PAD induction	3	10	8	4	24	26
B maintenance¹⁸	0	4	1	1	5	24
PAD induction	10	17	3	5	16	17
LP consolidation
L maintenance¹⁹	16	6	0	2	1	9
BCD induction²⁰	13	25	12	7	7
BTD induction				3	10	3
BTD consolidation²¹				0.6	0.6	1.2
BTD PACE induction				11	14
BTD PACE consolidation²²				6	10
Drug combinations
MPT induction	17-43 (any hematologic toxicity)			2-6	1-6	4-20
BMP induction²⁴	40	37	19	1	13	10	6*
BMPT induction	38	22	10	5	8	13
BT maintenance¹¹	2.6	0.6	0	2	5.3	1.3
BLD induction²⁵	9	6	2	4.5	7.5	2
LD induction¹²	12	6	8	26	2	16
Ld induction¹²	20	5	7	12	2	9
MPL induction	35†	11†	3†	3	0	11	7‡
L maintenance¹³	7†	6†	4†	2	0	3	7‡
CLd induction²⁶	12	10	18	10	0	6
Maintenance regimens after stem cell transplantation
L maintenance²⁷	51	14	3	3	1	8	8.5§
L maintenance²⁸	45	14	5				7.8§
Maintenance regimens after drug combinations
BT maintenance²⁹	0	0	0	1	7	2
BP maintenance²⁹	0	0	0	0	2	2

Regimen	Grade 3-4 hematologic toxicities			Grade 3-4 nonhematologic toxicities
Regimen	Neutropenia, %	Thrombocytopenia, %	Anemia, %	Thromboembolism, %	Neuropathy, %	Infection, %	Second primary cancer, %
Stem cell transplantation
BD¹⁷	5	2.9	4.2	1.7	7.1	8.8
PAD induction	3	10	8	4	24	26
B maintenance¹⁸	0	4	1	1	5	24
PAD induction	10	17	3	5	16	17
LP consolidation
L maintenance¹⁹	16	6	0	2	1	9
BCD induction²⁰	13	25	12	7	7
BTD induction				3	10	3
BTD consolidation²¹				0.6	0.6	1.2
BTD PACE induction				11	14
BTD PACE consolidation²²				6	10
Drug combinations
MPT induction	17-43 (any hematologic toxicity)			2-6	1-6	4-20
BMP induction²⁴	40	37	19	1	13	10	6*
BMPT induction	38	22	10	5	8	13
BT maintenance¹¹	2.6	0.6	0	2	5.3	1.3
BLD induction²⁵	9	6	2	4.5	7.5	2
LD induction¹²	12	6	8	26	2	16
Ld induction¹²	20	5	7	12	2	9
MPL induction	35†	11†	3†	3	0	11	7‡
L maintenance¹³	7†	6†	4†	2	0	3	7‡
CLd induction²⁶	12	10	18	10	0	6
Maintenance regimens after stem cell transplantation
L maintenance²⁷	51	14	3	3	1	8	8.5§
L maintenance²⁸	45	14	5				7.8§
Maintenance regimens after drug combinations
BT maintenance²⁹	0	0	0	1	7	2
BP maintenance²⁹	0	0	0	0	2	2

Abbreviations are explained in Table 1.

Incidence in the BMP arm at 5 years.

Grade 4 only.

Incidence in the whole MPL-L arm at 3 years.

Incidence in the lenalidomide arm at 3 years.